Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced Intensity Conditioning HSCT for Severe Sickle Cell Disease
NCT02776202Phase 2Unknown
- Sponsor
- Ministry of National Guard Health Affairs
- Start
- May 2016
- Primary completion
- Dec 2019
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fludarabine, antithymocyte globulin, melphalan in sickle cell disease (SCD), sponsored by Ministry of National Guard Health Affairs. Status: unknown.
02
Drugs
fludarabineantithymocyte globulinmelphalan
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02776202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02776202.